Hormonal treatments for major depressive disorder: state of the art
Major depressive disorder is a common psychiatric disorder associated with marked
suffering, morbidity, mortality, and cost. The World Health Organization projects that by 2030 …
suffering, morbidity, mortality, and cost. The World Health Organization projects that by 2030 …
Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data
Background The benefits and risks of testosterone treatment for women with diminished
sexual wellbeing remain controversial. We did a systematic review and meta-analysis to …
sexual wellbeing remain controversial. We did a systematic review and meta-analysis to …
Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline
Objective: To update practice guidelines for the therapeutic use of androgens in women.
Participants: A Task Force appointed by the Endocrine Society, American Congress of …
Participants: A Task Force appointed by the Endocrine Society, American Congress of …
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 6 …
Background: The Canadian Network for Mood and Anxiety Treatments (CANMAT)
conducted a revision of the 2009 guidelines by updating the evidence and …
conducted a revision of the 2009 guidelines by updating the evidence and …
Pharmacological interventions and hormonal therapies for depressive symptoms in peri-and post-menopausal women: a network meta-analysis of randomized …
Although significant portion of women experience depressive symptoms during or after
menopausal transition, there has been considerable controversy over the benefits of …
menopausal transition, there has been considerable controversy over the benefits of …
The integrative management of treatment-resistant depression: a comprehensive review and perspectives
Background: Major depressive disorder is a prevalent and disabling illness. Notwithstanding
numerous advances in the pharmacological treatment of depression, approximately 70% of …
numerous advances in the pharmacological treatment of depression, approximately 70% of …
Management of depressive symptoms in peri-and postmenopausal women: EMAS position statement
Introduction Globally, the total number of people with depression exceeds 300 million, and
the incidence rate is 70% greater in women. The perimenopause is considered to be a time …
the incidence rate is 70% greater in women. The perimenopause is considered to be a time …
Hormone therapy and mood in perimenopausal and postmenopausal women: a narrative review
E Toffol, O Heikinheimo, T Partonen - Menopause, 2015 - journals.lww.com
Objective Between 15% and 50% of women experience depressive symptoms during the
menopausal transition; in 15% to 30% of perimenopausal women, they are severe enough …
menopausal transition; in 15% to 30% of perimenopausal women, they are severe enough …
Menopausal hormone therapy and the mind: the role of hormone replacement in the prevention and treatment of cognitive decline, dementia, and cognitive …
Menopause has been associated with subjective cognitive dysfunction and elevated rates of
depression. While menopausal hormone therapy (MHT) is Food and Drug Administration …
depression. While menopausal hormone therapy (MHT) is Food and Drug Administration …
Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era
Importance of the field: Treatment-resistant depression (TRD) is common and debilitating.
Initial treatment is often insufficient to achieve full remission in a given depressive episode …
Initial treatment is often insufficient to achieve full remission in a given depressive episode …